<a href="https://laohu8.com/S/MLTX">MoonLake Immunotherapeutics</a> Faces Securities Fraud Class Action
A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024 and September 29, 2025. The complaint alleges that the company made false statements and concealed key information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure would not deliver superior clinical benefits or efficacy compared to the traditional monoclonal structure of BIMZELX. The lawsuit contends that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority over monoclonal antibodies. The legal action seeks to recover damages for affected investors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1117417) on December 15, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。